Evidence map›Paper›PMID 31373007›Full record

ArticleElectrophoresis2019

Analysis of thrombin-antithrombin complex formation using microchip electrophoresis and mass spectrometry.

Jacob B Nielsen, Anna V Nielsen, Richard H Carson, Hsien-Jung L Lin, Robert L Hanson, Mukul Sonker, Daniel N Mortensen, John C Price, Adam T Woolley

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Electrophoresis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jacob B NielsenDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Anna V NielsenDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Richard H CarsonDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Hsien-Jung L LinDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Robert L HansonDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Mukul SonkerDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Daniel N MortensenDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
John C PriceDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Adam T WoolleyDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.ORCID 0000-0002-4699-8094
Brigham Young University · US

Funding

Phase-Changing Sacrificial Layer Microfluidics for Enhanced Protein AnalysisR01EB006124 · NIBIB · BRIGHAM YOUNG UNIVERSITY · PI WOOLLEY, ADAM THOMAS · 2006 to 2016
$3.1M
3D-Printed Integrated Microfluidic Devices for Preterm Birth Biomarker AnalysisR01EB027096 · NIBIB · BRIGHAM YOUNG UNIVERSITY · PI WOOLLEY, ADAM THOMAS · 2018 to 2021
$1.1M
Brigham Young University for the use of the Integrated Microfabrication Lab facilitiesNIBIB NIH HHS R01 EB006124NIBIB NIH HHS R01 EB027096NIH HHS R01 EB006124NIH HHS R01 EB027096Undergraduate Research Assistantship from Brigham Young University
6 · The paper itself

Abstract

Preterm birth (PTB) related health problems take over one million lives each year, and currently, no clinical analysis is available to determine if a fetus is at risk for PTB. Here, we describe the preparation of a key PTB risk biomarker, thrombin-antithrombin (TAT), and characterize it using dot blots, MS, and microchip electrophoresis (µCE). The pH for fluorescently labeling TAT was also optimized using spectrofluorometry and spectrophotometry. The LOD of TAT was measured in µCE. Lastly, TAT was combined with six other PTB risk biomarkers and separated in µCE. The ability to make and characterize TAT is an important step toward the development of an integrated microfluidic diagnostic for PTB risk.

Indexed as

Antithrombin IIIBiomarkersElectrophoresis, MicrochipHumansLimit of DetectionMass SpectrometryPeptide HydrolasesPoint-of-Care SystemsAntithrombin IIIantithrombin III-protease complexBiomarkersPeptide HydrolasesBiomarkersDisease diagnosisDot blotPoint-of-care diagnosticsProtein surface modification

Identifiers

PMID31373007
PMCPMC6829041
OpenAlexW2965992349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.